True Capital Management’s AbbVie ABBV Stock Holding History

True Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$271K	Buy	+1,699	New	+$260K	0.19%	102

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

True Capital Management's ABBV Position: Q1 2023 in Review

True Capital Management opened a new position in AbbVie (ABBV) in Q1 2023: 1,699 shares worth $271K. The stake represents 0.19% of the portfolio and ranks #102 among its holdings.

3,138 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

True Capital Management held 1,699 shares of AbbVie worth $271K as of Q1 2023.
AbbVie was a new True Capital Management position in Q1 2023.
AbbVie made up 0.19% of True Capital Management's portfolio in Q1 2023, its #102 holding.
3,138 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on True Capital Management's 13F filing for Q1 2023, filed 2 May 2023.